1142363-52-7|Edicotinib|4-Cyano-1H-imidazole-2-carboxylic acid N-(2-(4,4-dimethylcyclohex-1-enyl)-6-(2,2,6,6-tetramethyltetrahydropyran-4-yl)pyridin-3-yl)amide|-范德生物科技公司

Edicotinib

NMR下载 COA and HPLC MSDS下载
names：
4-Cyano-1H-imidazole-2-carboxylic acid N-(2-(4,4-dimethylcyclohex-1-enyl)-6-(2,2,6,6-tetramethyltetrahydropyran-4-yl)pyridin-3-yl)amide
CAS号：
1142363-52-7
MDL Number：
MF(分子式)： C27H35N5O2 MW(分子量)： 461.61
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	Edicotinib
英文别名	JNJ40346527; JNJ 40346527; JNJ-40346527; Edicotinib;
CAS号	1142363-52-7
Inchi	InChI=1S/C27H35N5O2/c1-25(2)11-9-17(10-12-25)22-21(32-24(33)23-29-16-19(15-28)30-23)8-7-20(31-22)18-13-26(3,4)34-27(5,6)14-18/h7-9,16,18H,10-14H2,1-6H3,(H,29,30)(H,32,33)
InchiKey	BNVPFDRNGHMRJS-UHFFFAOYSA-N
分子式 Formula	C27H35N5O2
分子量 Molecular Weight	461.61
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	Edicotinib(CAS:1142363-52-7):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	Edicotinib, also known as JNJ-40346527, is a small molecule and orally available inhibitor of colony-stimulating factor-1 receptor (CSF1R; FMS) with potential antineoplastic activity. FMS tyrosine kinase inhibitor JNJ-40346527 blocks the receptor-ligand interaction between FMS and its ligand CSF1, thereby preventing autophosphorylation of FMS. As a result, unphosphorylated FMS cannot activate FMS-mediated signaling pathways, thus potentially inhibiting cell proliferation in FMS-overexpressed tumor cells.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Pass HI, Lavilla C, Canino C, Goparaju C, Preiss J, Noreen S, Blandino G,Cioce M. Inhibition of the colony-stimulating-factor-1 receptor affects theresistance of lung cancer cells to cisplatin. Oncotarget. 2016 Jul 28. doi:10.18632/oncotarget.10895. [Epub ahead of print] PubMed PMID: 27486763.

[2]Genovese MC, Hsia E, Belkowski SM, Chien C, Masterson T, Thurmond RL, MantheyCL, Yan XD, Ge T, Franks C, Greenspan A. Results from a Phase IIA Parallel GroupStudy of JNJ-40346527, an Oral CSF-1R Inhibitor, in Patients with ActiveRheumatoid Arthritis despite Disease-modifying Antirheumatic Drug Therapy. JRheumatol. 2015 Oct;42(10):1752-60. doi: 10.3899/jrheum.141580. Epub 2015 Aug 1.PubMed PMID: 26233509.

[3] von Tresckow B, Morschhauser F, Ribrag V, Topp MS, Chien C, Seetharam S,Aquino R, Kotoulek S, de Boer CJ, Engert A. An Open-Label, Multicenter, PhaseI/II Study of JNJ-40346527, a CSF-1R Inhibitor, in Patients with Relapsed orRefractory Hodgkin Lymphoma. Clin Cancer Res. 2015 Apr 15;21(8):1843-50. doi:10.1158/1078-0432.CCR-14-1845. Epub 2015 Jan 27. PubMed PMID: 25628399.

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开